Cumberland Pharmaceuticals

Nasdaq CPIX · Nashville,, TN

Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Immunology · Infectious disease · Metabolic & endocrine · Respiratory

Cumberland Pharmaceuticals is a clinical trial sponsor based in Nashville,, TN, listed as Nasdaq CPIX. It has 2 active clinical trials with 162 planned participants, across 8 therapeutic areas. Since 2021 it has completed 6 trials and stopped 1 early.

Trial track record · since 2021

2Active trials162 planned participants
6Completed7 with results posted
1Stopped early14% of finished trials

Financials · Nasdaq CPIX

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Pipeline · 2 active trials

StageTrialStatus

On the market

1 approved drug application with a product on the market.

Questions about Cumberland Pharmaceuticals

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-02.

Approve Suite is not affiliated with Cumberland Pharmaceuticals.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.